3.4(top 10%)
impact factor
895(top 20%)
papers
32.4K(top 10%)
citations
83(top 10%)
h-index
3.5(top 10%)
impact factor
961
all documents
34.5K
doc citations
130(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1Neurogenesis and Exercise: Past and Future DirectionsNeuroMolecular Medicine2008521
2An Overview of APP Processing Enzymes and ProductsNeuroMolecular Medicine2010515
3Functional Alterations in Memory Networks in Early Alzheimer’s DiseaseNeuroMolecular Medicine2010497
4Role of Neurotrophic Factors in the Etiology and Treatment of Mood DisordersNeuroMolecular Medicine2004463
5Excitotoxic and Excitoprotective Mechanisms: Abundant Targets for the Prevention and Treatment of Neurodegenerative DisordersNeuroMolecular Medicine2003415
6Role of Protein Aggregation in Mitochondrial Dysfunction and Neurodegeneration in Alzheimer's and Parkinson's DiseasesNeuroMolecular Medicine2003410
7Differential Expression of Oxidative Phosphorylation Genes in Patients With Alzheimer's Disease: Implications for Early Mitochondrial Dysfunction and Oxidative DamageNeuroMolecular Medicine2004361
8Hormetic Dietary PhytochemicalsNeuroMolecular Medicine2008285
9Manganese and its Role in Parkinson’s Disease: From Transport to NeuropathologyNeuroMolecular Medicine2009258
10Neurological Benefits of Omega-3 Fatty AcidsNeuroMolecular Medicine2008248
11Leukocyte Recruitment and Ischemic Brain InjuryNeuroMolecular Medicine2010239
12Physical Activity and the Regulation of Neurogenesis in the Adult and Aging BrainNeuroMolecular Medicine2008224
13Nicotinamide Prevents NAD+ Depletion and Protects Neurons Against Excitotoxicity and Cerebral Ischemia: NAD+ Consumption by SIRT1 may Endanger Energetically Compromised NeuronsNeuroMolecular Medicine2009222
14Oxidative Stress and β-Amyloid Protein in Alzheimer’s DiseaseNeuroMolecular Medicine2011222
15Disruption of Neurogenesis in the Subventricular Zone of Adult Mice,and in Human Cortical Neuronal Precursor Cells in Culture, by Amyloid β-Peptideby Amyloid β-PeptideNeuroMolecular Medicine2002218
16Energetics and Oxidative Stress in Synaptic Plasticity and Neurodegenerative DisordersNeuroMolecular Medicine2002209
17Neuroplasticity of Dopamine Circuits After Exercise: Implications for Central FatigueNeuroMolecular Medicine2008198
18Mitochondrial Medicine for Aging and Neurodegenerative DiseasesNeuroMolecular Medicine2008197
19Botanical Phenolics and Brain HealthNeuroMolecular Medicine2008189
20Advances in the Cellular and Molecular Biology of the Beta-Amyloid Protein in Alzheimer 's DiseaseNeuroMolecular Medicine2002181
21Oxidative Stress-Induced Signaling Pathways Implicated in the Pathogenesis of Parkinson’s DiseaseNeuroMolecular Medicine2014175
22Central Mechanisms of HPA Axis Regulation by Voluntary ExerciseNeuroMolecular Medicine2008171
23The Sympathetic Nervous System and PainNeuroMolecular Medicine2008170
24Cannabinoid Receptors and Their Role in NeuroprotectionNeuroMolecular Medicine2005169
25Phospholipases A2 and Inflammatory Responses in the Central Nervous SystemNeuroMolecular Medicine2010169
26Adverse Stress, Hippocampal Networks, and Alzheimer’s DiseaseNeuroMolecular Medicine2010169
27T-Cells in Alzheimer's DiseaseNeuroMolecular Medicine2005167
28Mitochondrial UCP4 Mediates an Adaptive Shift in Energy Metabolism and Increases the Resistance of Neurons to Metabolic and Oxidative StressNeuroMolecular Medicine2006167
29Neurotrophic Mechanisms in Drug AddictionNeuroMolecular Medicine2004164
30Brain-Derived Neurotrophic Factor and Alzheimer’s Disease: Physiopathology and BeyondNeuroMolecular Medicine2011162
31Stroke and T-CellsNeuroMolecular Medicine2005161
32The Serotonergic System and AnxietyNeuroMolecular Medicine2004153
33From Manganism to Manganese-Induced Parkinsonism: A Conceptual Model Based on the Evolution of ExposureNeuroMolecular Medicine2009150
34Clinical and electrophysiological aspects of Charcot-Marie-Tooth diseaseNeuroMolecular Medicine2006149
35Pathomechanisms of mutant proteins in Charcot-Marie-Tooth diseaseNeuroMolecular Medicine2006148
36Roles of AMP-activated Protein Kinase in Alzheimer’s DiseaseNeuroMolecular Medicine2012146
37Curcumin Nanoparticles Attenuate Neurochemical and Neurobehavioral Deficits in Experimental Model of Huntington’s DiseaseNeuroMolecular Medicine2014146
38Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative DiseasesNeuroMolecular Medicine2008140
39Synaptic Depression and Aberrant Excitatory Network Activity in Alzheimer’s Disease: Two Faces of the Same Coin?NeuroMolecular Medicine2010138
40The Role of the Complement System and the Activation Fragment C5a in the Central Nervous SystemNeuroMolecular Medicine2010136
41Mood Disorders and Obesity: Understanding Inflammation as a Pathophysiological NexusNeuroMolecular Medicine2011135
42The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-β Plaque and Glial Pathology in a Mouse Model of Alzheimer’s DiseaseNeuroMolecular Medicine2013134
43Exercise, Learned Helplessness, and the Stress-Resistant BrainNeuroMolecular Medicine2008133
44Metal Ion Physiopathology in Neurodegenerative DisordersNeuroMolecular Medicine2009131
45Mammalian Neutral Sphingomyelinases: Regulation and Roles in Cell Signaling ResponsesNeuroMolecular Medicine2010129
46Increased 5-Methylcytosine and Decreased 5-Hydroxymethylcytosine Levels are Associated with Reduced Striatal A2AR Levels in Huntington’s DiseaseNeuroMolecular Medicine2013129
47The Role of the Ceramide Acyl Chain Length in Neurodegeneration: Involvement of Ceramide SynthasesNeuroMolecular Medicine2010128
48Protein Accumulation in Traumatic Brain InjuryNeuroMolecular Medicine2003126
49Rett Syndrome and MeCP2NeuroMolecular Medicine2014124
50Kernicterus and the Molecular Mechanisms of Bilirubin-Induced CNS Injury in NewbornsNeuroMolecular Medicine2006122